Introduction
Before 1990s, the primary treatment for patients with bilateral retinoblastoma was enucleation of the more severely affected eye, without visual potential, and external-beam radiation therapy (EBRT) for the other eye. However, EBRT significantly increases the risk for second malignancies in patients with bilateral retinoblastoma who have a germline predisposition to cancer. 1 The risk of second malignancies is reported as 38.2% by 50 years of age in patients who receive EBRT. 2 In addition, EBRT compromises the development of the orbit and facial bones resulting in facial deformity. Therefore, chemotherapy followed by various local therapies has been used in patients with bilateral retinoblastoma to avoid EBRT. In patients with Reese-Ellsworth (RE) group I-III tumors, ocular salvage rates approach 100% with chemoreduction and local therapy. However, in patients with RE group IV or V tumors, ocular salvage rates are 40-60%. EBRT is used eventually in many patients with bilateral advanced retinoblastoma despite the risk of second cancers. [3] [4] [5] [6] When EBRT fails to control tumor growth, bilateral enucleation is unavoidable. According to a study reported by Lee et al., 6 41.7% patients, with bilateral advanced retinoblastoma (RE group IV or V), eventually lost both eye globes. Therefore, in patients with advanced disease in both eyes, novel salvage therapy is needed to avoid EBRT and bilateral enucleation.
High-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) has improved the survival of children with high-risk solid tumors. [7] [8] [9] [10] This treatment strategy is based on the hypothesis that a dose escalation might improve the survival of children with high-risk solid tumors. Recently, investigators have examined the efficacy of double or tripletandem HDCT/ASCR for further improvements in the outcome of patients with high-risk solid tumors. Sung et al. 8, 9 reported improved long-term survival using tandem HDCT/ASCR in patients with advanced neuroblastoma and high-risk brain tumors. Kletzel et al. 10 also reported improved survival in a single-arm trial of triple-tandem HDCT/ASCR in patients with high-risk neuroblastoma. They demonstrated that further dose escalation using sequential HDCT/ASCR might result in additional improvements in the survival of patients with high-risk tumors.
As retinoblastoma is a chemosensitive tumor, a strategy using HDCT/ASCR might be effective in the treatment of bilateral advanced retinoblastoma. In the present study, tandem HDCT/ASCR was used for treatment in patients with bilateral advanced retinoblastoma as a novel salvage treatment to avoid EBRT and bilateral enucleation when at least one eye could not be saved after chemoreduction and local therapy. As a result, all patients with bilateral advanced retinoblastoma had at least one functional eye globe without EBRT.
Patients and methods

Patients
Between January 2001 and December 2006, 66 children were diagnosed with retinoblastoma; there were 14 cases of tumors in both eyes. The diagnosis was confirmed by the typical clinical presentation and ophthalmologic examination under general anesthesia. Each affected eye was classified according to the RE classification. Ultrasonography of the globes, magnetic resonance imaging, cerebrospinal fluid cytology, technetium-99 bone scanning and BM examination were routine procedures used to define the tumor size and extent.
Chemoreduction Table 1 provides a summary of the chemotherapy regimens. The primary chemotherapy regimens employed for chemoreduction were CEDC until 2004 and ICEV from 2005 onward. When tumors were responsive and showed a significant decrease in size, and the patients were expected to have at least one functional eye after chemoreduction and local therapy, chemotherapy was continued until the tumor disappeared, or until local therapy could control the tumor. If the tumor response was not satisfactory with the primary chemoreduction regimen, the treatment regimen was changed (Table 2) . Each chemotherapy cycle was scheduled to be 28 days apart. However, delays were permitted to allow for the recovery of ANC to 1.0 Â 10 9 /l and the platelet count to 100 Â 10 9 /l. The patients received 5-10 mg/kg of human G-CSF daily if ANC fell below 0.5 Â 10 9 /l after the chemotherapy. When successful tumor control was not achieved with chemoreduction and local therapy, tandem HDCT/ASCR was planned instead of EBRT.
Ophthalmologic evaluation and treatment
The response to chemoreduction was assessed with bimonthly ophthalmologic examinations under general anesthesia and ultrasonography of the globes. Each tumor was evaluated for basal diameter, thickness and regression Abbreviations: C 1 ¼ the first cycle of chemotherapy; C 6 ¼ the sixth cycle of chemotherapy; C ¼ cryotherapy; EFS ¼ event-free survival of each eye globe; HDCT 1 ¼ the first high-dose chemotherapy; HDCT 2 ¼ the second high-dose chemotherapy; L ¼ left eye; NA ¼ not assessable; P ¼ laser photocoagulation; R ¼ right eye; RE ¼ Reese-Ellsworth; S ¼ subconjunctival carboplatin injection; SRF ¼ subretinal fluid; T ¼ thermotherapy; UPN ¼ unique patient number; VS ¼ vitreous seeds. a Macular zone was defined as the part of the retina between the superior and inferior temporal arterioles. The equatorial zone spanned from the borders of the macular zone to the equator. The ora location included the remaining anterior portion of the retina up to the ora serrata. b Tumor size: basal diameter Â height of the largest tumor, which was measured by ultrasonography. c Regression type of the enucleated eye was assessed after the second HDCT and regression type of the remaining eye was assessed at the last examination. d Data were not available due to incomplete examination. e Mass increased and involved more than 90% of retina after HDCT/ASCR. Mass was too small to be measured by ultrasonograpy. g There were six tumors in the right eye. Three tumors were in the equatorial region around the optic disc and the remaining three tumors were in the ora zone. h Eye globe was nearly filled with tumor and basal diameter could not be measured by ultrasonograpy.
type. 11 Cryotherapy, laser photocoagulation, subconjunctival carboplatin or transpupillary thermotherapy was provided whenever it was possible according to the indications for local therapy. 12 Enucleation was deferred after tandem HDCT/ASCR unless extrascleral invasion was suspected at diagnosis or unless the tumor was at risk for progression due to a poor response to the chemotherapy.
Collection of PBSCs
We attempted to collect at least 5 Â 10 6 CD34 þ cells/kg for rescue of patients receiving double HDCT, with PBSCs collected during a single leukapheresis round. Two or three more cycles of chemotherapy were administered, after collection of the PBSCs for scheduling HDCT/ASCR or trying to further decrease the tumor burden before HDCT/ASCR. Table 1 ). The second HDCT/ASCR was performed only if the platelet count exceeded 50 Â 10 9 /l after the first HDCT/ASCR without a transfusion and there was no evidence of significant organ dysfunction. Roughly, half of the PBSCs collected during a single leukapheresis round were infused for marrow rescue at each of the HDCT sessions. The toxicities during HDCT were graded using the National Cancer Institute's Common Toxicity Criteria. Written informed consent was obtained from the parents of each patient, and Samsung Medical Center Institutional Review Board approved the protocol used for HDCT/ASCR.
Results
Patient characteristics
The median age of all 14 patients (11 boys and 3 girls) was 9 months (range: 2-22) at diagnosis. Five out of 14 patients had either RE group IV or V tumors in both eyes. The remaining nine patients had RE group IV or V tumors in one eye and RE group I-III tumors in the other eye ( Table 2 ). The median number of retinal tumors per eye was one (range: 1-6). The median basal diameter and thickness of the largest tumor were 14.9 mm (range: 1.8-23.5) and 6.2 mm (range: 0.8-22.0), respectively. Vitreous seeds were present in 13 of 28 eyes (46.4%), subretinal seeds in 4 of 28 eyes (14.3%) and subretinal fluid in 12 of 28 eyes (42.9%).
Response to chemoreduction A median of 7 cycles (range: 6-13) of chemotherapy was administered. In two patients (UPN 8 and 9 ), the more severely affected eyes were enucleated before HDCT/ASCR, because the response to chemotherapy was very poor and the tumors were at risk for progression.
In three patients (UPN 6, 8 and 9), the tumor size decreased minimally after chemoreduction (median reduction in basal diameter and thickness: 6.4 and 4.3%, respectively) and the tumors in both eyes, or in the only remaining eye, were still not controllable with local therapy. In four patients (UPN 1, 2, 3 and 4) , the tumor size decreased significantly (median reduction in basal diameter and thickness: 40.8 and 61.1%, respectively); however, the tumors in both eyes were still not controllable with local therapy due to their size or location (overhanging or close to the macula or optic disc). Because the salvage of at least one functional eye globe was not achieved in these seven patients, with chemoreduction and local therapy, they were assigned to receive HDCT/ASCR. In two patients (UPN 5 and 7) who had RE group Vb tumors in one eye and RE II or III in the other eye, control of the less severely affected eye was expected with local therapy after chemoreduction, although it was impossible to treat the more severely affected eye with local therapy. The ophthalmologist recommended enucleation of the more severely affected eye and local therapy of the eye less severely affected, but the parents of these patients refused enucleation. Therefore, the patients were assigned to receive HDCT/ASCR. Nine out of 14 patients were assigned to receive HDCT/ASCR.
In the remaining five patients who had RE Vb tumor in one eye and RE I or II tumor in the other eye at diagnosis, it was possible to control the eye that was less severely affected by giving local therapy after chemoreduction, although the more severely affected eye required enucleation.
PBSC collection
A median of 14.7 Â 10 6 CD34 þ cells/kg (range: 5.5-58.2) was collected during a median of three leukapheresis procedures (range: 3-8). Generally, the leukapheresis procedure was well tolerated and no patient developed significant toxicity except for thrombocytopenia requiring transfusion after leukapheresis.
Tandem HDCT/ASCR
The median age at the first HDCT/ASCR was 20 months (range: 9-30) and 24 months (range: 11-34) at the second HDCT/ASCR. The second HDCT was performed at a median of 98 days (range: 49-123) after the first HDCT. The median number of infused CD34 þ cells was 9.2 Â 10 6 /kg (range: 2.7-29.9) and 5.4 Â 10 6 /kg (range: 2.0-28.3) at the first and second HDCT/ASCR, respectively. Neutrophil engraftment, defined as the first of 3 consecutive days of an ANC of at least 0.5 Â 10 9 /l, occurred at a median of 9 days (range: 9-11) and 10 days (range: 9-11) after the first and second HDCT/ASCR, respectively. Platelet engraftment, defined as the first of 7 consecutive days of a platelet count of at least 20 Â 10 9 /l sustained without a transfusion, occurred at a median of 17 days (range: 14-26) and 20 days (range: 17-38) after the first and second HDCT/ ASCR, respectively. Neutropenic fever developed after all 18 HDCT/ASCR, but was easily controlled without any evidence of a microbiologically documented infection (Table 3) . Although hepatic veno-occlusive disease (VOD) developed in two patients after the second HDCT/ASCR using BU, there was no treatment-related death. There was no second malignancy detected during a median of 42 months (range: 22-82) follow-up after the diagnosis.
Outcome of tandem HDCT/ASCR
In eight of nine patients who received tandem HDCT/ ASCR, local therapy was possible in at least one eye after the tandem HDCT/ASCR. In the remaining one patient (UPN 8), local therapy was not possible in the only remaining eye due to both tumor size and location even after the tandem HDCT/ASCR; however, the tumor with type 3 regression remained progression-free for 16 months after the second HDCT/ASCR. In two patients (UPN 1  and 6 ), the eye with a type 3 regression tumor and no visual potential, which could not be controlled with local therapy even after tandem HDCT/ASCR, was enucleated. Enucleation was also performed in two patients (UPN 3 and 7) after the tandem HDCT/ASCR, because the tumors in the more severely affected eye progressed even after tandem HDCT/ASCR. In one patient (UPN 4), vitreous seeds developed 19 months after the second HDCT/ASCR, and the eye was eventually enucleated. As a result, all nine patients who received tandem HDCT/ASCR had at least one functional eye globe saved without EBRT (Figure 1 ). In addition, two patients (UPN 2 and 5) have both eye globes and their vision saved.
A residual mass (median diameter: 6.6 mm, range: 4.3-15.7 mm) remained in seven surviving eyes of six patients even after the tandem HDCT/ASCR and local therapy. Type 1 regression was observed in five eyes of four patients (UPN 2, 4, 5 and 6) and type 3 regression in two eyes of two patients (UPN 8 and 9 ). These two eyes with type 3 regression remained progression-free for 16 and 12 months, respectively, after the second HDCT/ASCR. Four out of eight eyes with vitreous seeds and three out of nine eyes with subretinal fluid at diagnosis in nine patients, who received tandem HDCT/ASCR, were saved ( Table 2 ).
Discussion
Although EBRT has been an effective treatment modality in patients with bilateral advanced retinoblastoma, it is associated with a very high risk of a second malignancy and orbital deformities. 2 Recently, chemoreduction and local therapy have been used as primary treatment modalities to avoid EBRT in patients with bilateral retinoblastoma. Although chemoreduction and local therapy have been effective in eyes with low-stage intraocular retinoblastoma, they are less effective in eyes with RE group IV and V tumors. As a result, eventually about 50% patients with bilateral advanced retinoblastoma require EBRT or bilateral enucleation. [3] [4] [5] [6] Therefore, a new strategy is necessary to avoid EBRT and bilateral enucleation in patients with bilateral advanced retinoblastoma.
In the present study, tandem HDCT/ASCR was used as a salvage treatment to avoid EBRT and bilateral LT was still not applicable to at least one eye (n=4).
LT was applicable to at least one eye (n=7).
Refused enucleation of the more affected eye (n=2).
The more affected eye was enucleated and the less affected eye was saved with LT (n=5).
LT became possible in one eye (n=2).
LT became possible in at least one eye (n=4).
LT became possible in the more affected eye (n=2).
Both eyes were saved (n=1).
One eye was saved (n=2).
Tumor progressed in the more affected eye which was enucleated (n=1).
Enucleation of the more affected eye (n=2).
One eye was saved (n=3).
LT was still not applicable to the only eye (n=1).
One eye remained progression free (n=1). enucleation when at least one functional eye was not saved after chemoreduction and local therapy and would require EBRT or bilateral enucleation for life-saving treatment.
The results of our study showed that all the patients who underwent tandem HDCT/ASCR had at least one functional eye without requiring EBRT. Although there have been several studies that employed HDCT/ASCR for the treatment of metastatic or relapsed retinoblastoma, [13] [14] [15] [16] this is the first study of HDCT/ASCR in patients with newly diagnosed bilateral advanced retinoblastoma without extraocular metastasis.
Vitreous seeds and subretinal fluid at diagnosis are known to be associated with a high chemoreduction failure rate. 3, 17, 18 Because the vitreous cavity and subretinal space are relatively avascular, they may not have sufficient access to chemotherapeutic agents. Failure to control disease in children with bilateral retinoblastoma may lead to the need for EBRT. In a report on 63 RE group Vb eyes (tumors with vitreous seeds) that were irradiated at the initial diagnosis, 33 eyes (52.4%) developed ocular complications and the ocular survival rate was 53.4% at 10 years. In addition, 29.7% patients with bilateral disease developed second malignancies. 19 In the present study, four out of eight eyes with vitreous seeds and three out of nine eyes with subretinal fluid were saved after treatment with tandem HDCT/ASCR. These findings suggest that HDCT might enable chemotherapeutic agents to reach the target areas in higher concentrations, including the vitreous cavity and subretinal space. However, long-term follow-up is needed to compare the ocular salvage rate and later toxicities between HDCT and EBRT.
In 15 eyes among nine patients who underwent tandem HDCT/ASCR, the tumors overlapped or were close to visually vital structures, such as the optic disc and the macula. In the present study, an adequate safety margin, from the macula or optic disc, for safe local therapy was not obtained after the chemoreduction. Although the reduction of the basal diameter of tumors, after HDCT, was modest (median 1.1 mm), the tumors were amenable to local therapy at fish-flesh-appearing areas in 9 out of 15 eyes. We presumed that higher concentrations of chemotherapeutic agents could be delivered to the macular area and the tumor margins further away from the optic disc and macula, achieving improved safety margins for local therapy. We also identified that fish-flesh-appearing areas did not regress completely even after tandem HDCT/ ASCR. This finding suggests that a multidisciplinary approach is necessary, although HDCT/ASCR is included in the treatment course.
In the present study, type 3 regression was observed in two out of seven surviving eyes with residual tumor after tandem HDCT/ASCR. Bechrakis et al. 20 reported that areas of nonviable retinoblastoma cells, with moderate differentiation, were observed in tumors with type 3 regression. However, according to the study by Demirici et al., 21 two out of eight eyes with type 3 regression contained viable tumor cells by histopathologic examination. These findings suggest that patients with type 3 regression require careful follow-up; the two tumors with type 3 regression in this study are currently progressionfree.
The findings of this study showed that the short-term complications of HDCT were tolerable. In our previous study on patients with neuroblastoma, a shorter interval between the first and second HDCT/ASCR was associated with a higher toxic death rate in the second HDCT/ASCR. 9 This suggests that sufficient rest after the first HDCT/ ASCR is needed when both first and second HDCT are intensive, as in our tandem HDCT regimen. Therefore, patients in the present study took sufficient rest after the first HDCT/ASCR, especially in the late period of the study. Hepatic VOD developed in two patients after the second HDCT/ASCR using BU. Then, we changed the second HDCT regimen from BM to CM (Table 1) , because we thought that the BU-containing regimen was one of the causes for hepatic VOD in our patients. Thereafter, no patient developed VOD. We also changed the first HDCT regimen from MEC to CTE because we intended to use different drugs in the first and second HDCT to avoid possible drug resistance and overlapping drug toxicities. Thiotepa was included in the first HDCT regimen because it penetrates well into the central nervous system, which is one of the sites of treatment failure in retinoblastoma. There was no treatment-related death and the frequencies of grade 3 and 4 toxicities during the second HDCT were similar to those during the first HDCT. These findings demonstrated that the tandem double HDCT/ASCR regimen used in our study was relatively safe and feasible.
The late toxicities of HDCT/ASCR, in patients with retinoblastoma, have not been well studied. We found no significant organ toxicities to date; however, long-term careful examination is needed to evaluate late toxicities of HDCT, such as renal impairment, hearing deficits and endocrine dysfunction. Prior studies of other malignancies have reported an 8-10% cumulative incidence of second malignancies after HDCT/ASCR. [22] [23] [24] [25] [26] The intensive chemotherapy used for treatment might induce a second malignancy in patients with a germline predisposition to cancer. In the study conducted by Kleinerman et al., 2 radiation increased the risk of second malignancies in patients with hereditary retinoblastoma, but there was no development of a subsequent malignancy among the hereditary patients treated with conventional chemotherapy alone. However, the risk of second malignancies after HDCT in patients with bilateral retinoblastoma remains uncertain. It can be presumed that the estimated cumulative rate of second malignancies, after HDCT, might be higher than in patients with other solid tumors. Therefore, longterm follow-up is needed to evaluate the risk of second malignancies in patients with bilateral retinoblastoma. Although there was no second malignancy in the present study during a median follow-up of 42 months (range: 22-82), second cancer rate after a median follow-up of 5-10 years will be decisive.
With the development of various local approaches, the eye salvage rate is increasing in patients with bilateral retinoblastoma. However, some patients still need EBRT to save at least one functional eye, even with the risk of second malignancies. The present study demonstrated that HDCT/ ASCR might be an effective treatment for bilateral advanced retinoblastoma, especially when it is impossible to save at least one functional eye with chemoreduction and local therapy alone, and EBRT is the only remaining treatment option. However, it is well known that HDCT causes various short-term complications, such as organ toxicities, infection and even TRM. If these short-term toxicities are acceptable and can be minimized, HDCT/ ASCR might be an alternative treatment option to EBRT.
The number of patients included in the present study was too small and the duration of follow-up was too short to draw reliable conclusions on the safety and efficacy of tandem HDCT/ASCR for the treatment of bilateral advanced retinoblastoma. Long-term follow-up and larger patient samples are needed to evaluate the safety and efficacy of HDCT/ASCR as an alternative treatment to EBRT.
